Grifols: Plasma Self-Sufficiency Is The Mispriced Catalyst
Grifols Q1 Revenue €1.7 Billion Down From €1.786 Billion YoY
'Grifols' Canadian License Restricted After Plasma Donor Deaths' - Bloomberg
Grifols' Chronos-PD Study Demonstrates That Biological Changes In Individuals With Parkinson's Disease Occur More Than A Decade Before Clinical Diagnosis, With Potential Future Implications For Early Detection And Intervention
Assessing Grifols (BME:GRF) Valuation After Recent Share Price Weakness
European Equities Traded in the US as American Depositary Receipts Little Changed in Friday Trading
Grifols SA (GRFS) (Full Year 2025) Earnings Call Highlights: Strong Revenue Growth Amidst ...
Grifols, S.A. (GIKLY) Q4 2025 Earnings Call Transcript
Grifols, S.A. 2025 Q4 - Results - Earnings Call Presentation
Grifols Expects Reaching Free Cash Flow Pre-M&A Pre-Dividends Of €500M-575M; 2027 Milestones Unchanged; 2026 Adjusted EBITDA Margin Of Over 25%
Is Grifols (BME:GRF) Pricing Reflect Its Long-Term Slide And DCF Upside Potential
European Equities Traded in the US as American Depositary Receipts Fall Sharply in Thursday Trading
Is Grifols (BME:GRF) Now An Opportunity After A 26.9% One Year Share Price Climb?
CORRECTION: JP Morgan Maintains Neutral on Grifols, Maintains $10 Price Target (Price Target Updated - Rating Originally Published on 8th Dec)
JP Morgan Maintains Neutral on Grifols, Lowers Price Target to $10
Grifols Achieved Clinical Self-Sufficiency In Egypt For Immunoglobulins, Albumin, And Coagulation Factors Through Grifols Egypt For Plasma Derivatives
European Equities Traded in the US as American Depositary Receipts Higher in Wednesday Trading
Grifols (BME:GRF): Examining Valuation After Recent Share Price Volatility
Guillain-Barre Syndrome Market Analysis Report 2025-2035: Grifols, CSL Behring, and Octapharma Drive Innovation and Strategic Expansion
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.